{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:00:12Z","timestamp":1793293212962,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Summarize recent advances in interventional oncology for the management of neuroendocrine tumor liver metastases (NETLMs), with a focus on evolving evidence for embolization and ablation, integration with systemic therapies, and emerging approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Recent studies have strengthened the role of liver-directed therapies within multidisciplinary NET care. Long-term data supports transarterial chemoembolization as an effective and repeatable line of therapy. Improved dosimetry techniques are refining radioembolization's role in NETLM treatment, improving outcomes while limiting long-term toxicities. Synergistic treatment combinations have demonstrated promising efficacy. New evidence for focal therapies, including radiation segmentectomy and histotripsy, may expand options for solitary and oligometastatic disease. Concurrent biopsy and molecular profiling increasingly inform treatment decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Interventional radiologists play an increasingly important role in NETLM management by providing tailored and targeted liver-directed therapies, improving patient outcomes, delaying the start of systemic therapies, and integrating with NET treatment plans. Ongoing studies will further define optimal treatment sequencing and patient selection while expanding interventional treatment options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11912-026-01822-2","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:46:47Z","timestamp":1787816807000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of Interventional Oncology in the Management of Neuroendocrine Tumors: 2026 Update"],"prefix":"10.1007","volume":"28","author":[{"given":"Daniel M.","family":"DePietro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Soulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"issue":"12","key":"1822_CR1","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1002\/ijc.30400","volume":"139","author":"M Riihim\u00e4ki","year":"2016","unstructured":"Riihim\u00e4ki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer. 2016;139(12):2679\u201386.","journal-title":"Int J Cancer"},{"issue":"11","key":"1822_CR2","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1007\/s40618-022-01872-w","volume":"45","author":"R Modica","year":"2022","unstructured":"Modica R, Scandurra C, Maldonato NM, Dolce P, Dipietrangelo GG, Centello R, et al. Health-related quality of life in patients with neuroendocrine neoplasms: a two-wave longitudinal study. J Endocrinol Invest. 2022;45(11):2193\u2013200.","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"1822_CR3","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.1210\/clinem\/dgaa760","volume":"106","author":"C Scandurra","year":"2021","unstructured":"Scandurra C, Modica R, Maldonato NM, Dolce P, Dipietrangelo GG, Centello R, Di Vito V, Bottiglieri F, de Cicco F, Giannetta E, Isidori AM. Quality of life in patients with neuroendocrine neoplasms: the role of severity, clinical heterogeneity, and resilience. J Clin Endocrinol Metabolism. 2021;106(1):e316\u201327.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"10","key":"1822_CR4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342.","journal-title":"JAMA Oncol"},{"issue":"8","key":"1822_CR5","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.pan.2019.09.015","volume":"19","author":"F Panzuto","year":"2019","unstructured":"Panzuto F, Pusceddu S, Faggiano A, Rinzivillo M, Brighi N, Prinzi N, et al. Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: a comparison between pancreatic and gastrointestinal localizations. Pancreatology. 2019;19(8):1067\u201373.","journal-title":"Pancreatology"},{"issue":"11","key":"1822_CR6","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.1007\/s00330-019-06246-0","volume":"29","author":"Y Luo","year":"2019","unstructured":"Luo Y, Ameli S, Pandey A, Khoshpouri P, Ghasabeh MA, Pandey P, Li Z, Hu D, Kamel IR. Semi-quantitative visual assessment of hepatic tumor burden can reliably predict survival in neuroendocrine liver metastases treated with transarterial chemoembolization. Eur Radiol. 2019;29(11):5804\u201312.","journal-title":"Eur Radiol"},{"issue":"1","key":"1822_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.hoc.2024.08.001","volume":"39","author":"CG Tran","year":"2025","unstructured":"Tran CG, Sherman SK, Chandrasekharan C, Howe JR. Surgical management of neuroendocrine tumor liver metastases. Hematology\/Oncology Clin. 2025;39(1):37\u201353.","journal-title":"Hematology\/Oncology Clin"},{"issue":"10022","key":"1822_CR8","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968\u201377.","journal-title":"Lancet"},{"issue":"12","key":"1822_CR9","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1752\u201363.","journal-title":"Lancet Oncol"},{"issue":"10446","key":"1822_CR10","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, Garc\u00eda-Burillo A. [177Lu] Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. lancet. 2024;403(10446):2807\u201317.","journal-title":"lancet"},{"issue":"7","key":"1822_CR11","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1200\/JCO.22.01013","volume":"41","author":"PL Kunz","year":"2023","unstructured":"Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, et al. Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211). J Clin Oncol. 2023;41(7):1359\u201369.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1822_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa2403991","volume":"392","author":"JA Chan","year":"2025","unstructured":"Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, et al. Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors. N Engl J Med. 2025;392(7):653\u201365.","journal-title":"N Engl J Med"},{"issue":"6","key":"1822_CR13","doi-asserted-by":"publisher","first-page":"e2515798","DOI":"10.1001\/jamanetworkopen.2025.15798","volume":"8","author":"A Dasari","year":"2025","unstructured":"Dasari A, Wallace K, Halperin DM, Maxwell J, Kunz P, Singh S, Chasen B, Yao JC. Epidemiology of neuroendocrine neoplasms in the US. JAMA Netw open. 2025;8(6):e2515798.","journal-title":"JAMA Netw open"},{"key":"1822_CR14","unstructured":"Abdel-Rahman O, Ghosh S. Measuring the improvement in overall survival among patients with advanced gastroenteropancreatic neuroendocrine tumors over the past two decades. Scandinavian J Gastroenterol 2026 Apr 13:1\u20137."},{"issue":"7","key":"1822_CR15","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.3390\/jcm9072302","volume":"9","author":"M Barat","year":"2020","unstructured":"Barat M, Cottereau AS, Kedra A, Dermine S, Palmieri LJ, Coriat R, Dautry R, Tselikas L, Soyer P, Dohan A. The role of interventional radiology for the treatment of hepatic metastases from neuroendocrine tumor: an updated review. J Clin Med. 2020;9(7):2302.","journal-title":"J Clin Med"},{"issue":"4","key":"1822_CR16","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.3390\/curroncol31040154","volume":"31","author":"CR Criss","year":"2024","unstructured":"Criss CR, Makary MS. Liver-directed locoregional therapies for neuroendocrine liver metastases: recent advances and management. Curr Oncol. 2024;31(4):2076\u201391.","journal-title":"Curr Oncol"},{"key":"1822_CR17","first-page":"1","volume-title":"Neuroendocrine Neoplasia","author":"D DePietro","year":"2025","unstructured":"DePietro D, Soulen M. Role of Liver-Directed Therapy in Neuroendocrine Neoplasms. In: Neuroendocrine Neoplasia. Cham: Springer Nature Switzerland; 2025. p. 1\u201346."},{"issue":"1","key":"1822_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000443612","volume":"104","author":"A Rinke","year":"2016","unstructured":"Rinke A, Wittenberg M, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival. Neuroendocrinology. 2016;104(1):26\u201332.","journal-title":"Neuroendocrinology"},{"issue":"3","key":"1822_CR19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB, Phan AT, Raderer M, Sedl\u00e1\u010dkov\u00e1 E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224\u201333.","journal-title":"N Engl J Med"},{"issue":"32","key":"1822_CR20","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1200\/JCO.2016.68.0702","volume":"34","author":"JC Yao","year":"2016","unstructured":"Yao JC, Pavel M, Lombard-Bohas C, Van Cutsem E, Voi M, Brandt U, et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study. J Clin Oncol. 2016;34(32):3906\u201313.","journal-title":"J Clin Oncol"},{"issue":"28","key":"1822_CR21","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, M\u00fcller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656\u201363.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1822_CR22","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501\u201313.","journal-title":"N Engl J Med"},{"key":"1822_CR23","unstructured":"Kunz PL, Catalano PJ, Nimeiri H, Fisher GA, Longacre TA, Suarez CJ, Yao JC, Kulke MH, Hendifar AE, Shanks JC, Shah MH. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211)."},{"key":"1822_CR24","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors","author":"National Comprehensive Cancer Network","year":"2026","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. Version 1.2026. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2026.","edition":"Version 1.2026"},{"issue":"1","key":"1822_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/OP-25-00133","volume":"22","author":"K Perez","year":"2026","unstructured":"Perez K, Del Rivero J, Kennedy EB, Basu S, Chauhan A, Connolly HM, et al. Symptom management for well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline. JCO Oncol Pract. 2026;22(1):19\u201335.","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"1822_CR26","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel M, O\u2019\u2019Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, \u00d6berg K. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172\u201385.","journal-title":"Neuroendocrinology"},{"issue":"7","key":"1822_CR27","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844\u201360.","journal-title":"Ann Oncol"},{"issue":"6","key":"1822_CR28","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/MPA.0000000000000850","volume":"46","author":"JR Strosberg","year":"2017","unstructured":"Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, et al. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas. 2017;46(6):707\u201314.","journal-title":"Pancreas"},{"issue":"7","key":"1822_CR29","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1097\/MPA.0000000000001597","volume":"49","author":"TR Halfdanarson","year":"2020","unstructured":"Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O\u2019Dorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49(7):863\u201381.","journal-title":"Pancreas"},{"issue":"3","key":"1822_CR30","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.jhep.2011.09.012","volume":"56","author":"B Guiu","year":"2012","unstructured":"Guiu B, Deschamps F, Aho S, Munck F, Dromain C, Boige V, et al. Liver\/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol. 2012;56(3):609\u201317.","journal-title":"J Hepatol"},{"issue":"2","key":"1822_CR31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00270-012-0424-y","volume":"36","author":"N Bhagat","year":"2013","unstructured":"Bhagat N, Reyes DK, Lin M, Kamel I, Pawlik TM, Frangakis C, Geschwind JF. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Interv Radiol. 2013;36(2):449\u201359.","journal-title":"Cardiovasc Interv Radiol"},{"issue":"3","key":"1822_CR32","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1148\/radiol.2018170962","volume":"288","author":"KK Devulapalli","year":"2018","unstructured":"Devulapalli KK, Fidelman N, Soulen MC, Miller M, Johnson MS, Addo E, El-Haddad G, Nutting C, Morrison J, Farsad K, Lokken RP. 90Y radioembolization for hepatic malignancy in patients with previous biliary intervention: multicenter analysis of hepatobiliary infections. Radiology. 2018;288(3):774\u201381.","journal-title":"Radiology"},{"issue":"21","key":"1822_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215366","volume":"13","author":"C Touloupas","year":"2021","unstructured":"Touloupas C, Faron M, Hadoux J, Deschamps F, Roux C, Ronot M, et al. Long term efficacy and assessment of tumor response of transarterial chemoembolization in neuroendocrine liver metastases: a 15-year monocentric experience. Cancers. 2021;13(21):5366.","journal-title":"Cancers"},{"issue":"7","key":"1822_CR34","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jvir.2007.04.018","volume":"18","author":"AT Ruutiainen","year":"2007","unstructured":"Ruutiainen AT, Soulen MC, Tuite CM, Clark TW, Mondschein JI, Stavropoulos SW, Trerotola SO. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol. 2007;18(7):847\u201355.","journal-title":"J Vasc Interv Radiol"},{"issue":"11","key":"1822_CR35","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s11605-008-0640-6","volume":"12","author":"SC Pitt","year":"2008","unstructured":"Pitt SC, Knuth J, Keily JM, McDermott JC, Weber SM, Chen H, et al. Hepatic neuroendocrine metastases: chemo-or bland embolization? J Gastrointest Surg. 2008;12(11):1951\u201360.","journal-title":"J Gastrointest Surg"},{"issue":"8","key":"1822_CR36","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1002\/cncr.21389","volume":"104","author":"S Gupta","year":"2005","unstructured":"Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey JN, Ajani JA. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104(8):1590\u2013602.","journal-title":"Cancer"},{"issue":"1","key":"1822_CR37","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12020-013-0130-9","volume":"47","author":"F Fiore","year":"2014","unstructured":"Fiore F, Del Prete M, Franco R, Marotta V, Ramundo V, Marciello F, Di Sarno A, Carrat\u00f9 AC, De Roseto L, Colao C, Faggiano A. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine. 2014;47(1):177\u201382.","journal-title":"Endocrine"},{"key":"1822_CR38","doi-asserted-by":"crossref","unstructured":"DePietro DM, Li X, Shamimi-Noori SM. Chemoembolization beyond hepatocellular carcinoma: what tumors can we treat and when? InSeminars in Interventional Radiology 2024 Feb (Vol. 41, No. 01, pp. 027\u201347). Thieme Medical Publishers, Inc.","DOI":"10.1055\/s-0043-1777716"},{"issue":"1","key":"1822_CR39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00270-016-1478-z","volume":"40","author":"JX Chen","year":"2017","unstructured":"Chen JX, Rose S, White SB, El-Haddad G, Fidelman N, Yarmohammadi H, Hwang W, Sze DY, Kothary N, Stashek K, Wileyto EP. Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival. Cardiovasc Interv Radiol. 2017;40(1):69\u201380.","journal-title":"Cardiovasc Interv Radiol"},{"issue":"4","key":"1822_CR40","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1159\/000507194","volume":"111","author":"R Kanabar","year":"2021","unstructured":"Kanabar R, Barriuso J, McNamara MG, Hubner RA, Valle JW, Lamarca A. Liver embolisation for patients with neuroendocrine neoplasms: systematic review. Neuroendocrinology. 2021;111(4):354\u201369.","journal-title":"Neuroendocrinology"},{"key":"1822_CR41","doi-asserted-by":"crossref","unstructured":"Soulen MC, Paul WE, Dey C, El-Haddad G, Garcia-Monaco R, Fidelman N, Avritscher R, Farsad K, Kothary N, While S, De CF. Randomized Embolization Trial for NeuroEndocrine Tumors (RETNET). InEndocrine Abstracts 2026 Mar 4 (Vol. 116). Bioscientifica.","DOI":"10.1530\/endoabs.116.C12"},{"issue":"12","key":"1822_CR42","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.hpb.2024.08.011","volume":"26","author":"SM Ruff","year":"2024","unstructured":"Ruff SM, Chang JY, Xu M, Ejaz AM, Dillhoff M, Pawlik TM, Makary MS, Rikabi A, Sukrithan V, Konda B, Cloyd JM. Trans-arterial embolization versus chemoembolization for neuroendocrine liver metastases: a propensity matched analysis. HPB. 2024;26(12):1505\u201314.","journal-title":"HPB"},{"issue":"1","key":"1822_CR43","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","volume":"15","author":"A Frilling","year":"2014","unstructured":"Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, Kwekkeboom D, Lau WY, Klersy C, Vilgrain V, Davidson B. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8\u201321.","journal-title":"Lancet Oncol"},{"key":"1822_CR44","doi-asserted-by":"crossref","unstructured":"V\u00e9die AL, Matteini F, Cros J, Burgio MD, Gr\u00e9gory J, Hentic O, Busse-C\u00f4t\u00e9 A, Raynaud L, Couvelard A, Rebours V, Ruszniewski P. Chemoembolization using streptozotocin versus embolization in metastatic NETs. Endocrine-related Cancer. 2025;32(12).","DOI":"10.1530\/ERC-25-0298"},{"issue":"1","key":"1822_CR45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00270-020-02642-y","volume":"44","author":"T Helmberger","year":"2021","unstructured":"Helmberger T, Golfieri R, Pech M, Pfammatter T, Arnold D, Cianni R, et al. Clinical application of trans-arterial radioembolization in hepatic malignancies in Europe: first results from the prospective multicentre observational study CIRSE registry for SIR-spheres therapy (CIRT). Cardiovasc Intervent Radiol. 2021;44(1):21\u201335.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"1822_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09302-z","volume":"22","author":"TY Wong","year":"2022","unstructured":"Wong TY, Zhang KS, Gandhi RT, Collins ZS, O\u2019Hara R, Wang EA, et al. Long-term outcomes following 90Y radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry. BMC Cancer. 2022;22(1):224.","journal-title":"BMC Cancer"},{"issue":"5","key":"1822_CR47","first-page":"679","volume":"63","author":"BM Schaarschmidt","year":"2022","unstructured":"Schaarschmidt BM, Wildgruber M, Kloeckner R, Nie J, Steinle V, Braat AJ, Lohoefer F, Kim HS, Lahner H, Weber M, Theysohn J. 90Y radioembolization in the treatment of neuroendocrine neoplasms: results of an international multicenter retrospective study. J Nucl Med. 2022;63(5):679\u201385.","journal-title":"J Nucl Med"},{"issue":"11","key":"1822_CR48","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.jvir.2017.07.008","volume":"28","author":"O Chansanti","year":"2017","unstructured":"Chansanti O, Jahangiri Y, Matsui Y, Adachi A, Geeratikun Y, Kaufman JA, Kolbeck KJ, Stevens JS, Farsad K. Tumor dose response in yttrium-90 resin microsphere embolization for neuroendocrine liver metastases: a tumor-specific analysis with dose estimation using SPECT-CT. J Vasc Interv Radiol. 2017;28(11):1528\u201335.","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"1822_CR49","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1007\/s00259-021-05642-3","volume":"49","author":"SC Ebbers","year":"2022","unstructured":"Ebbers SC, van Roekel C, Braat MN, Barentsz MW, Lam MG, Braat AJ. Dose\u2013response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases. Eur J Nucl Med Mol Imaging. 2022;49(5):1700\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"1822_CR50","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2967\/jnumed.124.267774","volume":"65","author":"M Watanabe","year":"2024","unstructured":"Watanabe M, Leyser S, Theysohn J, Schaarschmidt B, Ludwig J, Fendler WP, et al. Dose\u2013response relationship in patients with liver metastases from neuroendocrine neoplasms undergoing radioembolization with 90Y glass microspheres. J Nucl Med. 2024;65(8):1175\u201380.","journal-title":"J Nucl Med"},{"issue":"5","key":"1822_CR51","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jvir.2023.10.015","volume":"35","author":"PW Doyle","year":"2024","unstructured":"Doyle PW, Workman CS, Grice JV, McGonigle TW, Huang S, Borgmann AJ, Baker JC, Taylor JE, Brown DB. Partition dosimetry and outcomes of metastatic neuroendocrine tumors after yttrium-90 resin microsphere radioembolization. J Vasc Interv Radiol. 2024;35(5):699\u2013708.","journal-title":"J Vasc Interv Radiol"},{"issue":"1126","key":"1822_CR52","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20210403","volume":"94","author":"P Thakral","year":"2021","unstructured":"Thakral P, Sen I, Das SS, Manda D, Cb V, Malik D. Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease. Br J Radiol. 2021;94(1126):20210403.","journal-title":"Br J Radiol"},{"issue":"7","key":"1822_CR53","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/MNM.0000000000001696","volume":"44","author":"A Nautiyal","year":"2023","unstructured":"Nautiyal A, Jha AK, Konuparamban A, Mithun S, Srichandan T, Puranik A, Gala K, Shetty N, Kulkarni S, Rangarajan V. A dosimetric comparison of systemic peptide receptor radionuclide therapy and intra-arterial peptide receptor radionuclide therapy in patients with liver dominant gastroenteropancreatic neuroendocrine tumours. Nucl Med Commun. 2023;44(7):585\u201395.","journal-title":"Nucl Med Commun"},{"issue":"4","key":"1822_CR54","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.7150\/thno.112012","volume":"16","author":"J Zhang","year":"2026","unstructured":"Zhang J, Mensel B, Baum RP. Intra-arterial peptide receptor radionuclide therapy (IA-PRRT) in patients with SSTR-expressing neuroendocrine neoplasms: short-and long-term safety and efficacy for up to 13 years. Theranostics. 2026;16(4):1658.","journal-title":"Theranostics"},{"issue":"4","key":"1822_CR55","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00259-023-06467-y","volume":"51","author":"SC Ebbers","year":"2024","unstructured":"Ebbers SC, Barentsz MW, de Vries-Huizing DM, Versleijen MW, Klompenhouwer EG, Tesselaar ME, Stokkel MP, Brabander T, Hofland J, Moelker A, van Leeuwaarde RS. Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: an in-patient randomised controlled trial (LUTIA). Eur J Nucl Med Mol Imaging. 2024;51(4):1121\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"1822_CR56","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1093\/annonc\/mdr614","volume":"23","author":"JR Strosberg","year":"2012","unstructured":"Strosberg JR, Weber JM, Choi J, Campos TL, Valone TL, Han G, et al. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol. 2012;23(9):2335\u201341.","journal-title":"Ann Oncol"},{"issue":"4","key":"1822_CR57","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S1470-2045(20)30027-9","volume":"21","author":"AJ Braat","year":"2020","unstructured":"Braat AJ, Bruijnen RC, van Rooij R, Braat MN, Wessels FJ, van Leeuwaarde RS, van Treijen MJ, de Herder WW, Hofland J, Tesselaar ME, de Jong HW. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. Lancet Oncol. 2020;21(4):561\u201370.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1822_CR58","doi-asserted-by":"publisher","first-page":"e70034","DOI":"10.1111\/jne.70034","volume":"37","author":"WB Veldhuis","year":"2025","unstructured":"Veldhuis WB, Walter T, de Vries-Huizing DM, Theysohn J, Barton S, Ekkelenkamp ED, Lachachi B, de Jong RJ, van Golen LW, Lanzafame H, Milot L. PRRT plus holmium\u2010166\u2010SIRT (HEPAR PLuS) versus PRRT\u2010only in patients with metastatic neuroendocrine tumors: A propensity\u2010score matched analysis. J Neuroendocrinol. 2025;37(8):e70034.","journal-title":"J Neuroendocrinol"},{"issue":"9","key":"1822_CR59","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1002\/cncr.31192","volume":"124","author":"HS Kim","year":"2018","unstructured":"Kim HS, Shaib WL, Zhang C, Nagaraju GP, Wu C, Alese OB, Chen Z, Brutcher E, Renfroe M, El-Rayes BF. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. Cancer. 2018;124(9):1992\u20132000.","journal-title":"Cancer"},{"issue":"8","key":"1822_CR60","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/MPA.0000000000001115","volume":"47","author":"MC Soulen","year":"2018","unstructured":"Soulen MC, van Houten D, Teitelbaum UR, Damjanov N, Cengel KA, Metz DC. Safety and feasibility of integrating yttrium-90 radioembolization with capecitabine-temozolomide for grade 2 liver-dominant metastatic neuroendocrine tumors. Pancreas. 2018;47(8):980\u20134.","journal-title":"Pancreas"},{"issue":"1","key":"1822_CR61","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s00270-023-03614-8","volume":"47","author":"MC Soulen","year":"2024","unstructured":"Soulen MC, Teitelbaum UR, Mick R, Eads J, Mondschein JI, Dagli M, van Houten D, Damjanov N, Schneider C, Cengel K, Metz DC. Integrated capecitabine\u2013temozolomide with radioembolization for liver-dominant G2 NETs: long-term outcomes of a single-institution retrospective study. Cardiovasc Interv Radiol. 2024;47(1):60\u20138.","journal-title":"Cardiovasc Interv Radiol"},{"issue":"4","key":"1822_CR62","doi-asserted-by":"publisher","first-page":"R151","DOI":"10.1530\/EJE-14-0630","volume":"172","author":"T de Baere","year":"2015","unstructured":"de Baere T, Deschamps F, Tselikas L, Ducreux M, Planchard D, Pearson E, et al. GEP-NETS update: interventional radiology: role in the treatment of liver metastases from GEP-NETs. Eur J Endocrinol. 2015;172(4):R151-66.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1822_CR63","doi-asserted-by":"publisher","first-page":"378","DOI":"10.4158\/EP-2019-0394","volume":"26","author":"SF Perrodin","year":"2020","unstructured":"Perrodin SF, Renzulli MM, Maurer MH, Kim-Fuchs C, Candinas D, Beldi G, et al. Can microwave ablation be an alternative to resection for the treatment of neuroendocrine liver metastases? Endocr Pract. 2020;26(4):378\u201387.","journal-title":"Endocr Pract"},{"issue":"6","key":"1822_CR64","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13289","volume":"35","author":"S Matrood","year":"2023","unstructured":"Matrood S, Gress TM, Rinke A, Mahnken AH. Radiofrequency and microwave ablation controls hepatic oligoprogression of advanced gastroenteropancreatic neuroendocrine tumors. J Neuroendocrinol. 2023;35(6):e13289.","journal-title":"J Neuroendocrinol"},{"issue":"8","key":"1822_CR65","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00432-025-06274-y","volume":"151","author":"S Huiyi","year":"2025","unstructured":"Huiyi S, Feihang W, Sothea Y, Danyang Z, Zihao H, Junqi S, Zhiping Y, Yi C, Liang L, Wenquan W, Yuan J. Comparison of TACE alone versus TACE combined with synchronous ablation for neuroendocrine neoplasms with liver metastases. J Cancer Res Clin Oncol. 2025;151(8):227.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"1822_CR66","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jvir.2024.11.003","volume":"36","author":"AC Gordon","year":"2025","unstructured":"Gordon AC, Savoor R, Kircher SM, Kalyan A, Benson AB III, Hohlastos E, Desai KR, Sato K, Salem R, Lewandowski RJ. Yttrium-90 radiation segmentectomy for treatment of neuroendocrine liver metastases. J Vasc Interv Radiol. 2025;36(2):293\u2013300.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"1822_CR67","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/02656736.2022.2112309","volume":"39","author":"J Vidal-Jove","year":"2022","unstructured":"Vidal-Jove J, Serres X, Vlaisavljevich E, Cannata J, Duryea A, Miller R, et al. First-in-man histotripsy of hepatic tumors: the THERESA trial, a feasibility study. Int J Hyperthermia. 2022;39(1):1115\u201323.","journal-title":"Int J Hyperthermia"},{"issue":"3","key":"1822_CR68","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233051","volume":"312","author":"M Mendiratta-Lala","year":"2024","unstructured":"Mendiratta-Lala M, Wiggermann P, Pech M, Serres-Creixams X, White SB, Davis C, et al. The# HOPE4LIVER single-arm pivotal trial for histotripsy of primary and metastatic liver tumors. Radiology. 2024;312(3):e233051.","journal-title":"Radiology"},{"key":"1822_CR69","doi-asserted-by":"publisher","first-page":"110084","DOI":"10.1016\/j.surg.2026.110084","volume":"194","author":"E Liu","year":"2026","unstructured":"Liu E, von Breitenbuch P, Kemp A, Mauceri H, Whitely P, Burns J, Sanchez D, Ziemlewicz TJ. Histotripsy for neuroendocrine liver metastases: Early single-institution outcomes and safety. Surgery. 2026;194:110084.","journal-title":"Surgery"},{"issue":"14","key":"1822_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143712","volume":"15","author":"DG Varghese","year":"2023","unstructured":"Varghese DG, Del Rivero J, Bergsland E. Grade progression and intrapatient tumor heterogeneity as potential contributors to resistance in gastroenteropancreatic neuroendocrine tumors. Cancers (Basel). 2023;15(14):3712.","journal-title":"Cancers (Basel)"},{"key":"1822_CR71","doi-asserted-by":"crossref","unstructured":"DePietro DM, Kiefer RM, Weinfurtner K, Hung ML. Concurrent Biopsy During Liver-Directed Therapy: Considerations, Techniques, and Expanding Role in Clinical Practice. Dig Disease Interventions. 2026 Jan 22.","DOI":"10.1055\/a-2779-5302"},{"key":"1822_CR72","doi-asserted-by":"crossref","unstructured":"Thuemmler R, Ackerman D, Hunt S, Nadolski G, Metz D, Weinfurtner K, Li W, Yang Z, Soulen M, Gade T, DePietro D. Abstract 110 Safety and Clinical Implications of Concurrent Biopsy of Neuroendocrine Liver Metastases at the Time of Liver-Directed Therapy. J Vasc Interv Radiol. 2026;37(4).","DOI":"10.1016\/j.jvir.2026.108122"},{"issue":"11","key":"1822_CR73","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.jvir.2018.05.023","volume":"29","author":"E Ziv","year":"2018","unstructured":"Ziv E, Rice SL, Filtes J, Yarmohammadi H, Boas FE, Erinjeri JP, et al. DAXX mutation status of embolization-treated neuroendocrine tumors predicts shorter time to hepatic progression. J Vasc Interv Radiol. 2018;29(11):1519\u201326.","journal-title":"J Vasc Interv Radiol"},{"issue":"9","key":"1822_CR74","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1159\/000547041","volume":"115","author":"C Solivio","year":"2025","unstructured":"Solivio C, Yuan G, Rizzo AJ, Graham MK, Shenker L, Vista W, Gil A, Singh H, Alexander E, Gonzalez-Aguirre A, Latzman J. Loss of DAXX\/ATRX Protein Expression Results in Ischemia Resistance and Radiation Sensitivity in Pancreatic Neuroendocrine Tumor Cells and Is Associated with Improved Response to Trans-Arterial Radioembolization. Neuroendocrinology. 2025;115(9):730\u201340.","journal-title":"Neuroendocrinology"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01822-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01822-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01822-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T09:02:10Z","timestamp":1787821330000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01822-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1822"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01822-2","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"2 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"88"}}